Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

g dirucotide

(MBP8298) for the treatment of SPMS. The trial is fully recruited

with approximately 510 patients enrolled at 68 sites across the U.S.

To date, the DSMB has conducted three reviews of the data from this

trial and has recommended it continue.

- MINDSET-01: A phase II clinical trial evaluating dirucotide (MBP8298)

for the treatment of relapsing-remitting MS (RRMS). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in six countries across Europe. The DSMB

has completed six safety reviews to date and recommended that the

trial continue as per the protocol. Completion of the double-blind

phase of the trial is expected at the end of 2008 with results

anticipated in the first quarter of 2009.

Financial Results

The consolidated net income for the three months ended September 30, 2008 was $6.3 million or $0.07 per share compared with a net loss of $10.9 million or ($0.12) per share for the three months ended September 30, 2007. The consolidated net loss for the nine months ended September 30, 2008 was $0.8 million or ($0.01) per share compared with a loss of $35.5 million or ($0.43) per share for the same period in 2007.

Revenue for the three months ended September 30, 2008 was $16.1 million compared to $nil for the same period of 2007. Revenue for the nine months ended September 30, 2008 was $40.1 million compared to $nil for the same period of 2007. The revenue is the result of recognizing a portion of the upfront payment and development milestone for the positive interim analysis related to the MAESTRO-01 clinical trial received from the licensing agreement with Lilly.

Total consolidated expenses for the three months ended September 30, 2008 were $11.8 million compared to $10.6 million for the same period of 2007. Total consolidated expenses for the nine months
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ) ... the Executive Director of the Rothman Institute of ... of the Initiative for Patient Centered Innovation (iPCI), ... the Rothman Institute of Innovation and Entrepreneurship (within ... with FDU’s School of Pharmacy’s Center for Healthcare ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... the following Webcast:, What: Neurocrine Biosciences 3rd ... @ 5 p.m. Eastern 2 p.m. Pacific, Where: ... Internet -- Simply log on to the web at the address ... Claudia Woodworth, 858-617-7759 If you are unable to participate during the ...
... demand for health ... economics and market access support, BOSTON, Oct. 28 ... as Vice President., Mr. Barak brings 16 years of ... reimbursement strategies,for drugs, medical devices, and diagnostics in a wide ...
... Company Also Announces Completion of Enrollment in U.S. ... Chronic Hepatitis C,Genotype 1, TAMPA, Fla., Oct. ... today announced the presentation of studies,of nitazoxanide at ... for the Study of Liver Diseases (AASLD), also ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... in collaboration with scientists at the University of California, San ... protein switch that plays a crucial role in the development ... 8 issue of the journal Molecular Cell, provide a template ... switch, a protein called Scp1, at will. , "Scp1 is ...
... the plague and some forms of food poisoning "paralyze" the ... to a new study in the September 8, 2006 issue ... researchers found that these bacteria, which belong to the genus ... enzyme. That copycat protein blocks host cells' capacity to change ...
... in the open access journal PLoS Biology, Sagiv Shifman, Jonathan ... the mouse genome--one of the most detailed genetic maps now ... this map, they used two groups of mice: one consisting ... inbred lines (RI). Using the single nucleotide polymorphism (SNP) data ...
Cached Biology News:Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3Study illuminates how the plague bacteria causes disease 2Study illuminates how the plague bacteria causes disease 3Mapping the mouse genome 2
Topoisomerase II...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... General description: Dish uses include large-scale ... Compatible with PBA Flexys TM automated ... number is a new product number, created ... showing no availability yet, please order under ...
BD BioCoat Collagen IV 150 mm Culture Dishes...
Biology Products: